Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02324621 · ClinicalTrials.gov registry record · Phase 1
Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors
A Phase 1 study of Unspecified Adult Solid Tumor, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02324621 is a Phase 1 study of Unspecified Adult Solid Tumor that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 26 participants, below the 36-participant average among 3 other Unspecified Adult Solid Tumor trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02324621, a Phase 1 study of Unspecified Adult Solid Tumor, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the long-term side effects of the continuation of oral ONC201 in treating patients with solid tumors that have spread to other places in the body who have previously benefited from receiving this drug. Oral ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG Oral ONC201
Study Locations (1)
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-02-20 |
| Est. Completion | 2018-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02324621
The ClinicalTrials.gov registry entry for NCT02324621 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36-participant average among 3 other Unspecified Adult Solid Tumor trials with a reported enrollment target (28% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unspecified Adult Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT02324621 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT02324621 about?
NCT02324621 is a clinical study titled "Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors". This phase I trial studies the long-term side effects of the continuation of oral ONC201 in treating patients with solid tumors that have spread to other places in the body who have previously benefited from receiving this drug. Oral ONC201 may stop the growth of tumor cells by blocking some of the ...
What is the current status of trial NCT02324621?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2015-02-20. Estimated completion is 2018-10-23.
What conditions does trial NCT02324621 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor.
What interventions are being tested in trial NCT02324621?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), Oral ONC201 (DRUG).
Who is sponsoring clinical trial NCT02324621?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02324621 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases
ACTIVE NOT RECRUITING · Phase 1
-
Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.